RU2016100433A - КЛЕТКИ SC-β И КОМПОЗИЦИИ И СПОСОБЫ ДЛЯ ИХ СОЗДАНИЯ - Google Patents

КЛЕТКИ SC-β И КОМПОЗИЦИИ И СПОСОБЫ ДЛЯ ИХ СОЗДАНИЯ Download PDF

Info

Publication number
RU2016100433A
RU2016100433A RU2016100433A RU2016100433A RU2016100433A RU 2016100433 A RU2016100433 A RU 2016100433A RU 2016100433 A RU2016100433 A RU 2016100433A RU 2016100433 A RU2016100433 A RU 2016100433A RU 2016100433 A RU2016100433 A RU 2016100433A
Authority
RU
Russia
Prior art keywords
cell
glucose
cells
pancreatic
stimulation
Prior art date
Application number
RU2016100433A
Other languages
English (en)
Other versions
RU2692595C2 (ru
Inventor
Куинн П. ПЕТЕРСОН
Фелиция Джей. ПАЙЛИУКА
Дуглас А. Мелтон
Джеффри Р. МИЛЛМАН
Майкл Сарис СЕГЕЛ
Мадс ГЮРТЛЕР
Original Assignee
Президент Энд Феллоус Оф Гарвард Колледж
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Президент Энд Феллоус Оф Гарвард Колледж filed Critical Президент Энд Феллоус Оф Гарвард Колледж
Publication of RU2016100433A publication Critical patent/RU2016100433A/ru
Application granted granted Critical
Publication of RU2692595C2 publication Critical patent/RU2692595C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0676—Pancreatic cells
    • C12N5/0678—Stem cells; Progenitor cells; Precursor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37—Digestive system
    • A61K35/39—Pancreas; Islets of Langerhans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0676—Pancreatic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0696—Artificially induced pluripotent stem cells, e.g. iPS
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/38—Vitamins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/11—Epidermal growth factor [EGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/117—Keratinocyte growth factors (KGF-1, i.e. FGF-7; KGF-2, i.e. FGF-12)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/15—Transforming growth factor beta (TGF-β)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/16—Activin; Inhibin; Mullerian inhibiting substance
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/375—Thyroid stimulating hormone [TSH]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/38—Hormones with nuclear receptors
    • C12N2501/385—Hormones with nuclear receptors of the family of the retinoic acid recptor, e.g. RAR, RXR; Peroxisome proliferator-activated receptor [PPAR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/38—Hormones with nuclear receptors
    • C12N2501/395—Thyroid hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/41—Hedgehog proteins; Cyclopamine (inhibitor)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/70—Enzymes
    • C12N2501/72—Transferases (EC 2.)
    • C12N2501/727—Kinases (EC 2.7.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998—Proteins not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/999—Small molecules not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/02—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from embryonic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/03—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from non-embryonic pluripotent stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/22—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from pancreatic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/45—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from artificially induced pluripotent stem cells

Claims (37)

1. Композиция, содержащая ненативную панкреатическую β-клетку, при этом:
(a) ненативная панкреатическая β-клетка содержит одну или более кристаллических инсулиновых гранул;
(b) ненативная панкреатическая β-клетка экспрессирует следующие гены: INS, PDX1, NKX6-1 и ZNT8; и
(c) ненативная панкреатическая β-клетка демонстрирует in vitro ответ, состоящий в стимулированной глюкозой секреции инсулина, на первую стимуляцию глюкозой.
2. Композиция по п. 1, отличающаяся тем, что ненативная панкреатическая β-клетка демонстрирует in vitro ответ, состоящий в стимулированной глюкозой секреции инсулина, на первую стимуляцию глюкозой, вторую стимуляцию глюкозой и третью стимуляцию глюкозой, при этом первую стимуляцию глюкозой, вторую стимуляцию глюкозой и третью стимуляцию глюкозой проводят последовательно.
3. Композиция по п. 1, отличающаяся тем, что ненативная панкреатическая β-клетка дополнительно экспрессирует по меньшей мере один ген, выбранный их группы, состоящей из MAFA, РАХ6, NEUROD1, GCK, SLC2A1, PCSK1, KCNJ11, АВСС8, SNAP25, RAB3A, GAD2, PTPRN, NKX2-2 и РАХ4.
4. Композиция по п. 1, отличающаяся тем, что ненативная панкреатическая β-клетка секретирует инсулин в ответ на первую концентрацию глюкозы по сравнению со второй концентрацией глюкозы в соотношении, составляющем по меньшей мере 1,1, при этом первая концентрация глюкозы выше, чем вторая концентрация глюкозы.
5. Композиция по п. 1, отличающаяся тем, что ненативная панкреатическая β-клетка является моногормональной.
6. Композиция по п. 1, отличающаяся тем, что количество инсулина, секретируемого ненативной панкреатической β-клеткой, составляет по меньшей мере 0,5 мкМЕ на 1000 клеток за 30 минут инкубации, при этом ненативную панкреатическую β-клетку обрабатывают по меньшей мере 20 мМ глюкозы.
7. Композиция по п. 1, отличающаяся тем, что секреция инсулина из ненативной панкреатической β-клетки повышается в ответ на противодиабетический агент.
8. Композиция по п. 1, отличающаяся тем, что ненативная панкреатическая β-клетка демонстрирует цитокин-индуцированный апоптоз в ответ на цитокин.
9. Композиция по п. 1, отличающаяся тем, что ненативная панкреатическая β-клетка характеризуется профилем генной экспрессии, который отличается от профиля генной экспрессии нативной β-клетки.
10. Популяция клеток, содержащая одну или более ненативных панкреатических β-клеток по п. 1, отличающаяся тем, что по меньшей мере 10% клеток в популяции клеток являются ненативными панкреатическими β-клетками.
11. Популяция клеток по п. 12, дополнительно содержащая инсулин-позитивные эндокринные клетки.
12. Популяция клеток по п. 12, отличающаяся тем, что популяция клеток содержит одну из следующих клеток:
a. С-пептид-негативную/глюкагон-позитивную клетку;
b. С-пептид-негативную/соматостатин-позитивную клетку;
c. глюкагон-позитивную/соматостатин-негативную клетку;
d. глюкагон-негативную/соматостатин-позитивную клетку; или
e. любую их комбинацию.
13. Популяция клеток по п. 12, отличающаяся тем, что по меньшей мере 3% популяции клеток составляют С-пептид-негативные/глюкагон-позитивные клетки или глюкагон-позитивные/соматостатин-негативные клетки.
14. Искусственные островок или поджелудочная железа, содержащие популяцию клеток по п. 12.
15. Способ дифференцировки клеток-предшественников в панкреатические β-клетки in vitro, включающий культивирование кластера клеток-предшественников в суспензии в культуральной среде, содержащей активатор сигнального пути тиреоидного гормона и ингибитор сигнального пути трансформирующего фактора роста β (TGF-β), вследствие чего происходит дифференцировка клеток-предшественников в панкреатические β-клетки, при этом панкреатические β-клетки демонстрируют in vitro ответ, состоящий в стимулированной глюкозой секреции инсулина, по меньшей мере на первую стимуляцию глюкозой.
16. Способ по п. 15, отличающийся тем, что клетки-предшественники включают инсулин-позитивную эндокринную клетку.
17. Способ по п. 15, отличающийся тем, что клетки-предшественники включают PDX1 -позитивную клетку-предшественник.
18. Способ по п. 15, отличающийся тем, что активатором сигнального пути тиреоидного гормона является трииодотиронин.
19. Способ по п. 18, отличающийся тем, что концентрация трииодотиронина составляет по меньшей мере 0,1 мМ.
20. Способ по п. 15, отличающийся тем, что ингибитором сигнального пути TGF-β является ингибитор II Alk5.
21. Способ по п. 20, отличающийся тем, что концентрация ингибитора II Alk5 составляет по меньшей мере 100 нМ.
22. Способ по п. 20, отличающийся тем, что концентрация ингибитора II Alk5 составляет 100 мкМ или меньше.
23. Способ по п. 15, отличающийся тем, что культивирование включает замену культуральной среды по меньшей мере через день.
24. Способ по п. 15, отличающийся тем, что культивирование длится по меньшей мере семь дней.
25. Способ по п. 15, отличающийся тем, что культуральная среда является бессывороточной культуральной средой.
26. Способ по п. 15, отличающийся тем, что клетки-предшественники культивируют в присутствии низкоадгезивного субстрата.
27. Способ по п. 15, отличающийся тем, что клетки-предшественники являются человеческими клетками-предшественниками.
28. Способ по п. 15, отличающийся тем, что панкреатические β-клетки демонстрируют in vitro ответ, состоящий в стимулированной глюкозой секреции инсулина, на первую стимуляцию глюкозой и вторую стимуляцию глюкозой, при этом первую стимуляцию глюкозой и вторую стимуляцию глюкозой проводят последовательно.
29. Способ по п. 15, отличающийся тем, что панкреатические β-клетки демонстрируют in vitro ответ, состоящий в стимулированной глюкозой секреции инсулина, на первую стимуляцию глюкозой, вторую стимуляцию глюкозой и третью стимуляцию глюкозой, при этом первую стимуляцию глюкозой, вторую стимуляцию глюкозой и третью стимуляцию глюкозой проводят последовательно.
RU2016100433A 2013-06-11 2014-06-11 КЛЕТКИ SC-β И КОМПОЗИЦИИ И СПОСОБЫ ДЛЯ ИХ СОЗДАНИЯ RU2692595C2 (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361833898P 2013-06-11 2013-06-11
US61/833,898 2013-06-11
US201461972212P 2014-03-28 2014-03-28
US61/972,212 2014-03-28
PCT/US2014/041992 WO2014201167A1 (en) 2013-06-11 2014-06-11 SC-β CELLS AND COMPOSITIONS AND METHODS FOR GENERATING THE SAME

Related Child Applications (1)

Application Number Title Priority Date Filing Date
RU2019117857A Division RU2813705C1 (ru) 2013-06-11 2014-06-11 КЛЕТКИ SC-β И КОМПОЗИЦИИ И СПОСОБЫ ДЛЯ ИХ СОЗДАНИЯ

Publications (2)

Publication Number Publication Date
RU2016100433A true RU2016100433A (ru) 2017-07-17
RU2692595C2 RU2692595C2 (ru) 2019-06-25

Family

ID=52022750

Family Applications (2)

Application Number Title Priority Date Filing Date
RU2016100219A RU2016100219A (ru) 2013-06-11 2014-06-11 КЛЕТКИ SC-β И КОМПОЗИЦИИ, И СПОСОБЫ ДЛЯ ИХ СОЗДАНИЯ
RU2016100433A RU2692595C2 (ru) 2013-06-11 2014-06-11 КЛЕТКИ SC-β И КОМПОЗИЦИИ И СПОСОБЫ ДЛЯ ИХ СОЗДАНИЯ

Family Applications Before (1)

Application Number Title Priority Date Filing Date
RU2016100219A RU2016100219A (ru) 2013-06-11 2014-06-11 КЛЕТКИ SC-β И КОМПОЗИЦИИ, И СПОСОБЫ ДЛЯ ИХ СОЗДАНИЯ

Country Status (17)

Country Link
US (14) US20170029778A1 (ru)
EP (3) EP3008170A4 (ru)
JP (7) JP6514689B2 (ru)
KR (12) KR102640729B1 (ru)
CN (4) CN112226402A (ru)
AU (6) AU2014278178B2 (ru)
BR (2) BR112015030946A8 (ru)
CA (2) CA2915091A1 (ru)
DE (2) DE202014011287U1 (ru)
DK (1) DK3008168T3 (ru)
GB (3) GB2549822B (ru)
HK (1) HK1257187B (ru)
MX (2) MX2015017103A (ru)
PH (1) PH12015502767A1 (ru)
RU (2) RU2016100219A (ru)
SG (3) SG11201510176VA (ru)
WO (2) WO2015002724A2 (ru)

Families Citing this family (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2185693B1 (en) 2007-07-31 2019-07-03 Lifescan, Inc. Differentiation of human embryonic stem cells
US9062290B2 (en) 2007-11-27 2015-06-23 Lifescan, Inc. Differentiation of human embryonic stem cells
JP6441080B2 (ja) 2011-12-22 2018-12-19 ヤンセン バイオテツク，インコーポレーテツド 単一ホルモンのインスリン陽性細胞へのヒト胚性幹細胞の分化
RU2684215C2 (ru) 2012-12-31 2019-04-04 Янссен Байотек, Инк. Способ получения панкреатических эндокринных клеток (варианты) и способ увеличения выхода бета-клеток
JP2016518357A (ja) 2013-04-08 2016-06-23 プレジデント アンド フェローズ オブ ハーバード カレッジ 骨格筋幹細胞を若返らせる方法および組成物
DE202014011287U1 (de) 2013-06-11 2019-02-06 The President And Fellows Of Harvard College SC-ß Zellen und Zusammensetzungen zur Erzeugung der Zellen
JP6588969B2 (ja) 2014-05-16 2019-10-09 ヤンセン バイオテツク，インコーポレーテツド 膵内分泌細胞内のｍａｆａ発現を強化するための小分子の使用
WO2016100898A1 (en) 2014-12-18 2016-06-23 President And Fellows Of Harvard College Serum-free in vitro directed differentiation protocol for generating stem cell-derived b cells and uses thereof
EP3234110B1 (en) 2014-12-18 2024-02-28 President and Fellows of Harvard College METHODS FOR GENERATING STEM CELL-DERIVED ß CELLS AND USES THEREOF
US20160175363A1 (en) * 2014-12-18 2016-06-23 President And Fellows Of Harvard College Methods for generating stem cell-derived beta cells and uses thereof
CN107614678B (zh) * 2014-12-18 2021-04-30 哈佛学院校长同事会 干细胞来源的β细胞的产生方法及其使用方法
US10196613B2 (en) 2014-12-19 2019-02-05 Regeneron Pharmaceuticals, Inc. Stem cells for modeling type 2 diabetes
ES2937168T3 (es) 2015-04-23 2023-03-24 Univ California La inducción controlada de progenitoras pancreáticas humanas produce células de tipo beta funcionales
PT3285572T (pt) * 2015-04-24 2021-03-04 Univ Copenhagen Método para a produção de células produtoras de insulina
CN107787363B (zh) * 2015-04-24 2021-06-25 哥本哈根大学 真正的胰腺祖细胞的分离
EP3328404A4 (en) * 2015-07-27 2018-12-26 The Regents of The University of California Methods and compositions for producing pancreatic beta cells
WO2017073740A1 (ja) * 2015-10-29 2017-05-04 学校法人埼玉医科大学 膵内分泌細胞の製造方法、及び分化転換剤
EP3386543B1 (en) 2015-11-10 2021-07-21 City of Hope Conditioning regimens and methods for inducing mixed chimerism
WO2017116569A1 (en) * 2015-12-31 2017-07-06 City Of Hope Methods for treating diabetes
CN116059320A (zh) * 2016-01-06 2023-05-05 哈佛学院校长同事会 使用gdf11的治疗防止体重增加、提高葡萄糖耐量并减轻脂肪肝
AU2017213795A1 (en) 2016-02-01 2018-08-16 Cedars-Sinai Medical Center Systems and methods for growth of intestinal cells in microfluidic devices
CN108699515A (zh) * 2016-02-24 2018-10-23 诺和诺德股份有限公司 由人多能干细胞衍生的内分泌祖细胞生成功能性β细胞
US10213511B2 (en) 2016-03-02 2019-02-26 Frequency Therapeutics, Inc. Thermoreversible compositions for administration of therapeutic agents
US10201540B2 (en) 2016-03-02 2019-02-12 Frequency Therapeutics, Inc. Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using GSK3 inhibitors: I
CA3014662A1 (en) * 2016-03-02 2017-09-08 Frequency Therapeutics, Inc. Methods for controlled proliferation of vestibular stem cells / generating inner ear hair cells using wnt and tgf-beta inhibition
MA45329A (fr) * 2016-04-08 2019-02-13 Univ California Production de cellules bêta matures pleinement fonctionnelles à partir de progénitrices pancréatiques humaines
US20190151371A1 (en) * 2016-06-09 2019-05-23 Georgetown University Process for continuous cell culture of islet cells
MA45502A (fr) * 2016-06-21 2019-04-24 Janssen Biotech Inc Génération de cellules bêta fonctionnelles dérivées de cellules souches pluripotentes humaines ayant une respiration mitochondriale glucose-dépendante et une réponse en sécrétion d'insuline en deux phases
WO2018140647A1 (en) 2017-01-25 2018-08-02 Cedars-Sinai Medical Center In vitro induction of mammary-like differentiation from human pluripotent stem cells
KR101745297B1 (ko) * 2017-02-02 2017-06-09 경북대학교 산학협력단 비만 진단용 조성물 및 이의 용도
US11767513B2 (en) 2017-03-14 2023-09-26 Cedars-Sinai Medical Center Neuromuscular junction
WO2018176001A2 (en) 2017-03-24 2018-09-27 Cedars-Sinai Medical Center Methods and compositions for production of fallopian tube epithelium
US10767164B2 (en) 2017-03-30 2020-09-08 The Research Foundation For The State University Of New York Microenvironments for self-assembly of islet organoids from stem cells differentiation
AU2018285539A1 (en) 2017-06-14 2020-02-06 Vertex Pharmaceuticals Incorporated Devices and methods for delivering therapeutics
WO2019005871A1 (en) * 2017-06-26 2019-01-03 City Of Hope METHODS FOR CULTURE OF CELLS OF THE ISLANDS OF LANGERHANS
US10391156B2 (en) 2017-07-12 2019-08-27 Viacyte, Inc. University donor cells and related methods
CA3070596A1 (en) * 2017-07-21 2019-01-24 Semma Therapeutics, Inc. Re-aggregation of stem cell-derived pancreatic beta cells
CA2983845C (en) 2017-10-26 2024-01-30 University Of Copenhagen Generation of glucose-responsive beta cells
AU2018370029A1 (en) 2017-11-15 2020-07-02 Vertex Pharmaceuticals Incorporated Islet cell manufacturing compositions and methods of use
AU2019228004A1 (en) * 2018-03-02 2020-10-22 Vertex Pharmaceuticals Incorporated Methods of enhancing stem cell differentiation into beta cells
US20210000880A1 (en) * 2018-03-23 2021-01-07 Cedars-Sinai Medical Center Methods of use of islet cells
EP3790956A4 (en) * 2018-05-11 2022-03-16 Cornell University PROCEDURE FOR DIFFERENTIATION OF HUMAN PLURIPOTENT STEM CELLS INTO MONOCLONAL CELLS
WO2020033879A1 (en) 2018-08-10 2020-02-13 Semma Therapeutics, Inc. Stem cell derived islet differentiation
CA3109647A1 (en) 2018-08-17 2020-02-20 Frequency Therapeutics, Inc. Compositions and methods for generating hair cells by upregulating jag-1
WO2020037326A1 (en) 2018-08-17 2020-02-20 Frequency Therapeutics, Inc. Compositions and methods for generating hair cells by downregulating foxo
WO2020043292A1 (en) * 2018-08-30 2020-03-05 Novo Nordisk A/S Generation of functional beta cells from human pluripotent stem cell-derived endocrine progenitors
US10724052B2 (en) 2018-09-07 2020-07-28 Crispr Therapeutics Ag Universal donor cells
AU2019342197A1 (en) 2018-09-21 2021-04-15 President And Fellows Of Harvard College Methods and compositions for treating diabetes, and methods for enriching mRNA coding for secreted proteins
JP2022511385A (ja) * 2018-09-28 2022-01-31 メモリアル スローン ケタリング キャンサー センター 幹細胞由来ヒトミクログリア細胞、作製する方法および使用方法
CN112888778A (zh) * 2018-10-15 2021-06-01 Cynity株式会社 通过低分子化合物由源自内胚层组织或器官的细胞制备干细胞/祖细胞的方法
KR102115960B1 (ko) * 2018-11-28 2020-05-27 송미연 인간 중간엽 줄기세포를 갑상선 호르몬 분비세포로 분화 방법
US20220175848A1 (en) 2019-04-01 2022-06-09 The Broad Institute, Inc. Methods and compositions for cell therapy
WO2020207998A1 (en) * 2019-04-08 2020-10-15 Novo Nordisk A/S Generation of pancreatic endoderm from stem cell derived definitive endoderm
KR102167257B1 (ko) * 2019-05-28 2020-10-19 부산대학교 산학협력단 토마티딘 처리를 통한 줄기세포의 성숙화된 심근세포로의 분화유도 촉진 방법
EP3976236A1 (en) 2019-05-31 2022-04-06 W.L. Gore & Associates Inc. A biocompatible membrane composite
EP3976237A1 (en) 2019-05-31 2022-04-06 W.L. Gore & Associates Inc. Cell encapsulation devices with controlled oxygen diffusion distances
WO2020243665A1 (en) 2019-05-31 2020-12-03 W. L. Gore & Associates, Inc. A biocompatible membrane composite
EP3975926A1 (en) 2019-05-31 2022-04-06 W.L. Gore & Associates, Inc. A biocompatible membrane composite
EP3980535A4 (en) * 2019-06-06 2023-06-21 President and Fellows of Harvard College COMPOSITIONS AND METHODS FOR MATURING BETA CELLS DERIVED FROM STEM CELLS
WO2020264072A1 (en) 2019-06-25 2020-12-30 Semma Therapeutics, Inc. Enhanced differentiation of beta cells
WO2021030424A1 (en) * 2019-08-13 2021-02-18 Semma Therapeutics, Inc. Pancreatic differentiation
US10740609B1 (en) * 2019-08-30 2020-08-11 Numerica Corporation System and method for space object detection in daytime sky images
CN114364791A (zh) 2019-09-05 2022-04-15 克里斯珀医疗股份公司 通用供体细胞
CA3150235A1 (en) 2019-09-05 2021-03-11 Alireza Rezania UNIVERSAL DONOR CELLS
AU2020361709A1 (en) * 2019-10-10 2022-05-26 The Regents Of The University Of Colorado, A Body Corporate Use of ENTPD3 for identification, isolation, and enhancing mature stem cell derived insulin-producing cells
US20230014430A1 (en) * 2019-11-20 2023-01-19 Washington University Methods and Compositions for Generating Functionally Mature Beta Cells and Uses Thereof
KR20220143063A (ko) 2020-02-19 2022-10-24 남미 테라퓨틱스, 인크. 암의 치료에 유용한 TGFβ 길항제 전구약물을 함유하는 제제화된 및/또는 공동-제제화된 리포솜 조성물 및 그의 방법
CN111269875B (zh) * 2020-03-24 2022-04-08 山东兴瑞生物科技有限公司 一种利用自体免疫细胞定向分化为胰岛细胞的方法
WO2021212044A1 (en) * 2020-04-16 2021-10-21 Washington University Methods and compositions for improving sc-beta cells or enhancing their utility
US20220010282A1 (en) * 2020-06-16 2022-01-13 The Broad Institute, Inc. Three-dimensional cell culture, devices, and use thereof
AU2021315814A1 (en) * 2020-07-31 2023-03-02 Vertex Pharmaceuticals Incorporated In vitro differentiation of pancreatic endocrine cells
EP4271796A1 (en) 2020-12-31 2023-11-08 CRISPR Therapeutics AG Universal donor cells
CN112980771B (zh) * 2021-03-05 2023-12-19 贝康医学科技有限公司 一种制备胰腺beta细胞的方法及其应用
CN112980774B (zh) * 2021-03-19 2022-04-01 上海爱萨尔生物科技有限公司 一种诱导多能干细胞定向分化制备胰岛β细胞的培养方法
CN113046299A (zh) * 2021-03-19 2021-06-29 上海爱萨尔生物科技有限公司 一种诱导多能干细胞定向分化制备胰岛β细胞的添加剂
CN112961823B (zh) * 2021-03-19 2024-01-23 上海爱萨尔生物科技有限公司 一种诱导多能干细胞定向分化制备胰岛β细胞的培养液
US20220403340A1 (en) * 2021-06-11 2022-12-22 Washington University Media for cryopreserved cells and methods of making and using same
US20220409855A1 (en) 2021-06-29 2022-12-29 Staffan Holmin Methods of delivering cells and therapeutic agents to organs and extravascular sites
WO2023048182A1 (en) 2021-09-21 2023-03-30 Okinawa Institute Of Science And Technology School Corporation Platforms for drug tests against synucleinopathy using human brain organoids
CA3234231A1 (en) 2021-10-21 2023-04-27 Vertex Pharmaceuticals Incorporated Hypoimmune cells
WO2023072170A1 (en) * 2021-10-28 2023-05-04 Sunshine Lake Pharma Co., Ltd. A METHOD FOR PROMOTING THE DIFFERENTIATION OF STEM CELLS INTO FUNCTIONALLY MATURE ISLET β CELLS AND USE THEREOF
WO2023077140A2 (en) 2021-11-01 2023-05-04 Vertex Pharmaceuticals Incorporated Stem cell derived pancreatic islet differentiation
WO2023097513A1 (en) * 2021-11-30 2023-06-08 Hangzhou Reprogenix Bioscience, Inc. Method of generating functional islets from pluripotent stem cells
WO2023150493A2 (en) * 2022-02-01 2023-08-10 Vertex Pharmaceuticals Incorporated Cell therapy for diabetes
WO2023199113A1 (en) 2022-04-15 2023-10-19 Smartcella Solutions Ab COMPOSITIONS AND METHODS FOR EXOSOME-MEDIATED DELIVERY OF mRNA AGENTS
WO2023235568A1 (en) * 2022-06-03 2023-12-07 Cornell University Derivation of glucose-responsive insulin-secreting cells and organoids from human stomach cells and their use to treat diabetes

Family Cites Families (166)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6774A (en) 1849-10-09 Improved jointed center-board
US130A (en) 1837-02-16 Improvement in metallic solutions for the preservation of timber
US3270960A (en) 1964-09-11 1966-09-06 Sperry Rand Corp Fluid sensor
DE1570610C3 (de) 1965-10-01 1974-08-01 Bayer Ag, 5090 Leverkusen Verfahren zur Herstellung von Poly-N-oxyden
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4391909A (en) 1979-03-28 1983-07-05 Damon Corporation Microcapsules containing viable tissue cells
US4378016A (en) 1981-07-15 1983-03-29 Biotek, Inc. Artificial endocrine gland containing hormone-producing cells
US5425764A (en) 1992-07-30 1995-06-20 The University Of Toledo Bioartificial pancreas
US6469017B1 (en) 1998-01-16 2002-10-22 Cell Therapeutics, Inc. Method of inhibiting interleukin-12 signaling
US7018419B2 (en) 1994-05-20 2006-03-28 Spielberg Theodore E Microporous encapsulated endocrine cell disks, biconcave disks and multidimpled chambers for hormonal replacement
US5843780A (en) 1995-01-20 1998-12-01 Wisconsin Alumni Research Foundation Primate embryonic stem cells
AU720662B2 (en) 1995-04-07 2000-06-08 Albert Einstein College Of Medicine Of Yeshiva University Recombinant B-cell and uses thereof
US6187991B1 (en) 1995-05-23 2001-02-13 Pfizer Inc Transgenic animal models for type II diabetes mellitus
CA2218623A1 (en) 1996-02-23 1997-08-28 Circe Biomedical, Inc. Novel artificial pancreas
US5994619A (en) 1996-04-01 1999-11-30 University Of Massachusetts, A Public Institution Of Higher Education Of The Commonwealth Of Massachusetts, As Represented By Its Amherst Campus Production of chimeric bovine or porcine animals using cultured inner cell mass cells
JP3869092B2 (ja) 1996-10-01 2007-01-17 ジェロン・コーポレーション ヒトテロメラーゼ触媒性サブユニット
US5945577A (en) 1997-01-10 1999-08-31 University Of Massachusetts As Represented By Its Amherst Campus Cloning using donor nuclei from proliferating somatic cells
WO1998030679A1 (en) 1997-01-10 1998-07-16 Life Technologies, Inc. Embryonic stem cell serum replacement
US6090622A (en) 1997-03-31 2000-07-18 The Johns Hopkins School Of Medicine Human embryonic pluripotent germ cells
AU1197699A (en) 1997-10-23 1999-05-10 Geron Corporation Methods and materials for the growth of primate-derived primordial stem cells
WO2001051611A1 (en) 2000-01-14 2001-07-19 Bresagen Limited Cell production
US6667176B1 (en) 2000-01-11 2003-12-23 Geron Corporation cDNA libraries reflecting gene expression during growth and differentiation of human pluripotent stem cells
US7410798B2 (en) 2001-01-10 2008-08-12 Geron Corporation Culture system for rapid expansion of human embryonic stem cells
GB0005251D0 (en) 2000-03-03 2000-04-26 Merck Sharp & Dohme Therapeutic compounds
US6436704B1 (en) 2000-04-10 2002-08-20 Raven Biotechnologies, Inc. Human pancreatic epithelial progenitor cells and methods of isolation and use thereof
GB2379447B (en) 2000-05-17 2004-12-29 Geron Corp Neural progenitor cell populations
US7094874B2 (en) 2000-05-26 2006-08-22 Bristol-Myers Squibb Co. Soluble CTLA4 mutant molecules
US6906810B2 (en) 2000-07-13 2005-06-14 Morgan Guaranty Trust Company Method and system for allowing an on-line user to selectively customize a document for printing in a single batch process
US7163918B2 (en) 2000-08-22 2007-01-16 New River Pharmaceuticals Inc. Iodothyronine compositions
US6905875B2 (en) 2000-10-12 2005-06-14 National University Of Singapore Non-disruptive three-dimensional culture and harvest system for anchorage-dependent cells
US20040060568A1 (en) 2000-10-13 2004-04-01 Henryk Dudek Hedgehog antagonists, methods and uses related thereto
US6576464B2 (en) 2000-11-27 2003-06-10 Geron Corporation Methods for providing differentiated stem cells
JP2005503759A (ja) 2001-01-24 2005-02-10 アメリカ合衆国 幹細胞の膵臓内分泌細胞への分化方法
CA2447015A1 (en) 2001-05-15 2002-11-21 Rappaport Family Institute For Research In The Medical Sciences Insulin producing cells derived from human embryonic stem cells
WO2003014313A2 (en) 2001-08-06 2003-02-20 Bresagen, Ltd. Alternative compositions and methods for the culture of stem cells
US20030054331A1 (en) 2001-09-14 2003-03-20 Stemsource, Inc. Preservation of non embryonic cells from non hematopoietic tissues
WO2003033697A1 (en) 2001-10-18 2003-04-24 Ixion Biotechnology, Inc. Conversion of liver stem and progenitor cells to pancreatic functional cells
US20030077256A1 (en) 2001-10-19 2003-04-24 Paul Czernichow Pancreas regeneration using embryonic pancreatic cells
US7157278B2 (en) 2001-12-04 2007-01-02 Organogenesis, Inc. Cultured cells from pancreatic islets
KR20120003961A (ko) 2001-12-07 2012-01-11 사이토리 테라퓨틱스, 인크. 처리된 리포애스퍼레이트 세포로 환자를 치료하기 위한 시스템 및 방법
EP2264146A1 (en) 2001-12-07 2010-12-22 Geron Corporation Islet cells from human embryonic stem cells
JP5364224B2 (ja) 2001-12-07 2013-12-11 ジェロン・コーポレーション ヒト胚性幹細胞に由来する造血細胞
US20060003446A1 (en) 2002-05-17 2006-01-05 Gordon Keller Mesoderm and definitive endoderm cell populations
JP2006512046A (ja) 2002-05-28 2006-04-13 ベクトン・ディキンソン・アンド・カンパニー ｉｎｖｉｔｒｏにおけるヒト膵臓腺房細胞の増殖およびインスリン産生細胞への分化転換のための方法
AU2003240810A1 (en) 2002-05-28 2003-12-12 Becton, Dickinson And Company Methods, compositions, and growth and differentiation factors for insulin-producing cells
EP1567639A4 (en) 2002-12-05 2005-12-21 Technion Res & Dev Foundation CULTURE OF HUMAN PANCREATIC ISLANDS AND USES THEREOF
WO2004058764A1 (en) 2002-12-27 2004-07-15 Bayer Healthcare Ag 4-phenyl-pyrimido [4,5-b] indole derivatives
US7172682B2 (en) 2003-01-24 2007-02-06 Rensselaer Polytechnic Institute Enzyme immobilization for electroosmotic flow
US20030224411A1 (en) 2003-03-13 2003-12-04 Stanton Lawrence W. Genes that are up- or down-regulated during differentiation of human embryonic stem cells
US7084246B2 (en) 2003-04-17 2006-08-01 Molecular Logix, Inc. Epidermal growth factor agonists
US7985585B2 (en) 2004-07-09 2011-07-26 Viacyte, Inc. Preprimitive streak and mesendoderm cells
US8647873B2 (en) 2004-04-27 2014-02-11 Viacyte, Inc. PDX1 expressing endoderm
US20050266554A1 (en) 2004-04-27 2005-12-01 D Amour Kevin A PDX1 expressing endoderm
US7625753B2 (en) 2003-12-23 2009-12-01 Cythera, Inc. Expansion of definitive endoderm cells
US7704738B2 (en) 2003-12-23 2010-04-27 Cythera, Inc. Definitive endoderm
US7541185B2 (en) 2003-12-23 2009-06-02 Cythera, Inc. Methods for identifying factors for differentiating definitive endoderm
US8586357B2 (en) 2003-12-23 2013-11-19 Viacyte, Inc. Markers of definitive endoderm
CN1950498A (zh) 2004-03-10 2007-04-18 加利福尼亚大学董事会 培养胚胎干细胞的组合物和方法
BRPI0509282A (pt) 2004-03-30 2007-09-18 Univ California compostos contendo hidrazida inibidores de cftr e seus usos
WO2005097977A2 (en) 2004-04-01 2005-10-20 Wisconsin Alumni Research Foundation Differentiation of stem cells to endoderm and pancreatic lineage
EP2377922B1 (en) 2004-04-27 2020-04-08 Viacyte, Inc. PDX1 expressing endoderm
EP1809739B1 (en) 2004-07-13 2014-10-15 Asterias Biotherapeutics, Inc. Medium for growing human embryonic stem cells
JP5102030B2 (ja) 2004-08-13 2012-12-19 ユニバーシティ・オブ・ジョージア・リサーチ・ファウンデイション・インコーポレイテッド ヒト胚性幹細胞における自己再生および分化のための組成物および方法
US7517870B2 (en) 2004-12-03 2009-04-14 Fondazione Telethon Use of compounds that interfere with the hedgehog signaling pathway for the manufacture of a medicament for preventing, inhibiting, and/or reversing ocular diseases related with ocular neovascularization
EP1676574A3 (en) 2004-12-30 2006-07-26 Johnson & Johnson Vision Care, Inc. Methods for promoting survival of transplanted tissues and cells
AU2006210955A1 (en) 2005-01-31 2006-08-10 Es Cell International Pte Ltd. Directed differentiation of embryonic stem cells and uses thereof
AU2006262369B2 (en) 2005-06-22 2012-07-05 Asterias Biotherapeutics, Inc. Suspension culture of human embryonic stem cells
JP5560393B2 (ja) 2005-06-22 2014-07-23 アステリアス バイオセラピューティクス インコーポレイテッド 心筋細胞系列細胞への霊長類多能性幹細胞の分化
CA2615836A1 (en) 2005-07-19 2007-01-25 Anjaparavanda Naren Lpa2 receptor agonist inhibitors of cftr
US20070122905A1 (en) 2005-10-27 2007-05-31 D Amour Kevin A PDX1-expressing dorsal and ventral foregut endoderm
ZA200804496B (en) 2005-12-16 2009-09-30 Alcon Inc Control of intraocular pressure using ALK5 modulation agents
WO2007075807A2 (en) 2005-12-20 2007-07-05 Es Cell International Pte Ltd. Methods for the directed differentiation of embryonic stem cell
DE602007011409D1 (de) 2006-01-20 2011-02-03 Reneuron Inc Verfahren für verbesserte zellproliferation von pankreas-vorläuferzellen in einer pankreaszellkultur
JPWO2007088651A1 (ja) 2006-02-01 2009-06-25 国立大学法人 東京大学 ＴＧＦ−βシグナル阻害剤と抗腫瘍剤の組み合せ使用
US7973011B2 (en) 2006-02-13 2011-07-05 The Board Of Trustees Of The Leland Stanford Junior University Blockade of gamma-secretase activity to promote myelination by oligodendrocytes
EP1994141B1 (en) 2006-02-23 2017-11-15 ViaCyte, Inc. Compositions and methods useful for culturing differentiable cells
US7695965B2 (en) 2006-03-02 2010-04-13 Cythera, Inc. Methods of producing pancreatic hormones
WO2007103282A2 (en) 2006-03-02 2007-09-13 Cythera, Inc. Endocrine precursor cells, pancreatic hormone-expressing cells and methods of production
WO2007109673A2 (en) 2006-03-20 2007-09-27 Stanford University Mutant epidermal growth factor polypeptides, nucleic acids, and uses therefor
CA2650812C (en) 2006-04-28 2017-12-12 Lifescan, Inc. Differentiation of human embryonic stem cells
WO2007139929A2 (en) 2006-05-25 2007-12-06 The Burnham Institute For Medical Research Methods for culture and production of single cell populations of human embryonic stem cells
AU2007254766A1 (en) * 2006-06-02 2007-12-13 University Of Georgia Research Foundation, Inc. Pancreatic and liver endoderm cells and tissue by differentiation of definitive endoderm cells obtained from human embryonic stems
US8415153B2 (en) 2006-06-19 2013-04-09 Geron Corporation Differentiation and enrichment of islet-like cells from human pluripotent stem cells
AU2007277364B2 (en) 2006-07-26 2010-08-12 Viacyte, Inc. Methods of producing pancreatic hormones
CA2662209C (en) 2006-08-29 2015-02-17 The University Of Akron Implantable devices for producing insulin
US9023984B2 (en) * 2006-12-29 2015-05-05 The Regents Of The University Of Colorado, A Body Corporate Diagnostic and therapeutic target for autoimmune diseases and uses thereof
WO2008102000A1 (en) * 2007-02-21 2008-08-28 Sarl Endocells Human pancreatic beta cell lines for diagnostic of diabetes
US8283351B2 (en) 2007-04-02 2012-10-09 Institute For Oneworld Health Cyclic and acyclic hydrazine derivatives compositions including them and uses thereof
EP3957716A1 (en) 2007-07-18 2022-02-23 Janssen Biotech, Inc. Differentiation of human embryonic stem cells
EP2185693B1 (en) 2007-07-31 2019-07-03 Lifescan, Inc. Differentiation of human embryonic stem cells
EA017495B1 (ru) 2007-08-09 2012-12-28 Кабусики Кайся Якулт Хонса ИНГИБИТОРЫ γ-СЕКРЕТАЗЫ
US7695963B2 (en) 2007-09-24 2010-04-13 Cythera, Inc. Methods for increasing definitive endoderm production
US8623650B2 (en) 2007-10-19 2014-01-07 Viacyte, Inc. Methods and compositions for feeder-free pluripotent stem cell media containing human serum
US9062290B2 (en) 2007-11-27 2015-06-23 Lifescan, Inc. Differentiation of human embryonic stem cells
SG154367A1 (en) 2008-01-31 2009-08-28 Es Cell Int Pte Ltd Method of differentiating stem cells
JP5638961B2 (ja) 2008-03-13 2014-12-10 ザ ジェネラル ホスピタル コーポレイション Ｂｍｐシグナル伝達経路のインヒビター
DK2283117T3 (da) 2008-04-21 2014-01-20 Viacyte Inc Fremgangsmåde til oprensning af pancreatiske endodermceller afledt fra humane embryoniske stamceller
US8338170B2 (en) 2008-04-21 2012-12-25 Viacyte, Inc. Methods for purifying endoderm and pancreatic endoderm cells derived from human embryonic stem cells
WO2009132083A2 (en) 2008-04-22 2009-10-29 President And Fellows Of Harvard College Compositions and methods for promoting the generation of pdx1+ pancreatic cells
US8623648B2 (en) 2008-04-24 2014-01-07 Janssen Biotech, Inc. Treatment of pluripotent cells
US20090298178A1 (en) 2008-06-03 2009-12-03 D Amour Kevin Allen Growth factors for production of definitive endoderm
ES2697798T3 (es) 2008-06-30 2019-01-28 Janssen Biotech Inc Diferenciación de células madre pluripotentes
WO2010022395A2 (en) * 2008-08-22 2010-02-25 President And Fellows Of Harvard College Methods of reprogramming cells
WO2010033906A2 (en) 2008-09-19 2010-03-25 President And Fellows Of Harvard College Efficient induction of pluripotent stem cells using small molecule compounds
CA2742268C (en) 2008-10-31 2020-02-18 Centocor Ortho Biotech Inc. Differentiation of human embryonic stem cells to the pancreatic endocrine lineage
CN102333862B (zh) * 2008-10-31 2018-04-27 詹森生物科技公司 人胚胎干细胞向胰腺内分泌谱系的分化
US8008075B2 (en) 2008-11-04 2011-08-30 Viacyte, Inc. Stem cell aggregate suspension compositions and methods of differentiation thereof
JP2012508584A (ja) 2008-11-14 2012-04-12 ヴィアサイト，インコーポレイテッド ヒト多能性幹細胞由来膵臓細胞のカプセル化
CA2744227C (en) * 2008-11-20 2018-10-02 Centocor Ortho Biotech Inc. Methods and compositions for cell attachment and cultivation on planar substrates
GB201111244D0 (en) * 2011-06-30 2011-08-17 Konink Nl Akademie Van Wetenschappen Knaw Culture media for stem cells
US8507274B2 (en) 2009-02-06 2013-08-13 President And Fellows Of Harvard College Compositions and methods for promoting the generation of definitive endoderm
JP2012524073A (ja) 2009-04-17 2012-10-11 スムマ ヘルス システムズ エルエルシー 眼球瘢痕化を抑制するための形質転換成長因子−β受容体阻害剤の使用
US20100272695A1 (en) * 2009-04-22 2010-10-28 Alan Agulnick Cell compositions derived from dedifferentiated reprogrammed cells
US9109245B2 (en) 2009-04-22 2015-08-18 Viacyte, Inc. Cell compositions derived from dedifferentiated reprogrammed cells
SG10201401864VA (en) 2009-04-27 2014-09-26 Viacyte Inc Small Molecules Supporting Pluripotent Cell Growth And Methods Thereof
WO2010135639A2 (en) * 2009-05-21 2010-11-25 Joslin Diabetes Center, Inc. Compositions and methods for promoting beta cell maturity
EP2456858B1 (en) * 2009-07-20 2018-08-29 Janssen Biotech, Inc. Differentiation of human embryonic stem cells
GB2485113B (en) 2009-07-20 2016-12-28 Janssen Biotech Inc Differentiation of human embryonic stem cells into cells of the pancreatic endoderm lineage
KR101861584B1 (ko) * 2009-10-29 2018-05-28 얀센 바이오테크 인코포레이티드 만능 줄기 세포
WO2011079017A2 (en) 2009-12-23 2011-06-30 Centocor Ortho Biotech Inc. Differentiation of human embryonic stem cells
SG10201501503VA (en) * 2010-03-01 2015-04-29 Janssen Biotech Inc Methods for purifying cells derived from pluripotent stem cells
JP5909482B2 (ja) 2010-03-31 2016-04-26 ザ スクリプス リサーチ インスティテュート 細胞の再プログラム
WO2011128897A1 (en) 2010-04-12 2011-10-20 Technion Research & Development Foundation Ltd. Populations of pancreatic progenitor cells and methods of isolating and using same
JP2013524836A (ja) 2010-04-25 2013-06-20 マウント・シナイ・スクール・オブ・メディスン 多能性細胞からの前部前腸内胚葉の生成
RU2663339C1 (ru) * 2010-05-12 2018-08-03 Янссен Байотек, Инк. Дифференцирование эмбриональных стволовых клеток человека
KR101877077B1 (ko) * 2010-08-09 2018-07-10 다케다 야쿠힌 고교 가부시키가이샤 췌호르몬-생성 세포의 제조 방법
DK2603226T3 (da) * 2010-08-12 2021-06-07 Janssen Biotech Inc Behandling af diabetes med endokrine pankreas-prækursorceller
GB201014169D0 (en) 2010-08-25 2010-10-06 Cambridge Entpr Ltd In vitro hepatic differentiation
BR112013004614A2 (pt) 2010-08-31 2024-01-16 Janssen Biotech Inc Diferenciação de células-tronco pluripotentes
EP3372672A1 (en) 2010-08-31 2018-09-12 Janssen Biotech, Inc. Differentiation of human embryonic stem cells
EP2611910B1 (en) 2010-08-31 2018-01-17 Janssen Biotech, Inc. Differentiation of human embryonic stem cells
WO2012044486A1 (en) 2010-09-28 2012-04-05 Baylor Research Institute Induction of pancreatic stem cells by transient overexpression of reprogramming factors and pdxi selection
EP2508607A1 (en) 2011-04-07 2012-10-10 Helmholtz-Zentrum für Infektionsforschung GmbH Medicament for liver regeneration and for treatment of liver failure
US20120270890A1 (en) * 2011-04-22 2012-10-25 Cheng-Ho Chung Methods of Pancreatic Beta Cell Regeneration
JP6147737B2 (ja) 2011-06-27 2017-06-14 アレクトス・セラピューティクス・インコーポレイテッド 選択的グリコシダーゼ阻害剤およびその使用
WO2013000085A1 (en) 2011-06-27 2013-01-03 Alectos Therapeutics Inc. Selective glycosidase inhibitors and uses thereof
WO2013018851A1 (ja) 2011-08-02 2013-02-07 独立行政法人国立がん研究センター 誘導肝幹細胞から肝分化誘導する方法及び誘導肝前駆細胞
WO2013052700A1 (en) 2011-10-04 2013-04-11 The Brigham And Women's Hospital, Inc. Novel sulfonamides
US9493743B2 (en) * 2011-10-18 2016-11-15 Univercell Biosolutions Production of a human beta cell line from an early post natal pancreas
WO2013071282A1 (en) 2011-11-13 2013-05-16 Blanchette Rockefeller Neurosciences Institute Pkc activators and combinations thereof
JP6441080B2 (ja) * 2011-12-22 2018-12-19 ヤンセン バイオテツク，インコーポレーテツド 単一ホルモンのインスリン陽性細胞へのヒト胚性幹細胞の分化
AU2013259706A1 (en) 2012-05-07 2014-10-30 Janssen Biotech, Inc. Differentiation of human embryonic stem cells into pancreatic endoderm
WO2013166654A1 (en) 2012-05-08 2013-11-14 Merck Sharp & Dohme Corp. Permeable glycosidase inhibitors and uses thereof
US9611275B2 (en) 2012-05-08 2017-04-04 Alectos Therapeutics, Inc. Permeable glycosidase inhibitors and uses thereof
EP2859091B1 (en) 2012-06-08 2018-08-29 Janssen Biotech, Inc. Differentiation of human embryonic stem cells into pancreatic endocrine cells
SG11201408150UA (en) 2012-06-14 2015-01-29 Janssen Biotech Inc Treatment of pluripotent cells
JP6470687B2 (ja) 2012-09-03 2019-02-13 ノヴォ ノルディスク アー／エス 小分子を用いた多能性幹細胞からの膵臓内胚葉の作製
WO2014105543A1 (en) * 2012-12-31 2014-07-03 Janssen Biotech, Inc. Culturing of human embryonic stem cells at the air-liquid interface for differentiation into pancreatic endocrine cells
MX2015008619A (es) 2012-12-31 2016-01-12 Janssen Biotech Inc Suspension y agrupamiento de celulas humanas pluripotentes para la diferenciacion a celulas endocrinas pancreaticas.
RU2684215C2 (ru) * 2012-12-31 2019-04-04 Янссен Байотек, Инк. Способ получения панкреатических эндокринных клеток (варианты) и способ увеличения выхода бета-клеток
WO2014130887A1 (en) 2013-02-22 2014-08-28 Cedars-Sinai Medical Center Pancreatic insulin-producing beta-cell lines derived from human pluripotent stem cells
US20140287944A1 (en) 2013-02-26 2014-09-25 President And Fellows Of Harvard College Markers for functionally mature beta-cells and methods of using the same
KR102334260B1 (ko) 2013-03-14 2021-12-02 스미토모 다이니폰 파마 온콜로지, 인크. Ｊａｋ2 및 ａｌｋ2 억제제 및 이들의 사용 방법
US8859286B2 (en) 2013-03-14 2014-10-14 Viacyte, Inc. In vitro differentiation of pluripotent stem cells to pancreatic endoderm cells (PEC) and endocrine cells
US20140329704A1 (en) 2013-03-28 2014-11-06 President And Fellows Of Harvard College Markers for mature beta-cells and methods of using the same
DE202014011287U1 (de) 2013-06-11 2019-02-06 The President And Fellows Of Harvard College SC-ß Zellen und Zusammensetzungen zur Erzeugung der Zellen
JP6636427B2 (ja) 2013-08-30 2020-01-29 ノヴォ ノルディスク アー／エス 小分子を用いるヒト多能性幹細胞からの内分泌始原細胞の作製
JP6588969B2 (ja) * 2014-05-16 2019-10-09 ヤンセン バイオテツク，インコーポレーテツド 膵内分泌細胞内のｍａｆａ発現を強化するための小分子の使用
AU2015267148B2 (en) 2014-05-28 2021-07-29 Children's Hospital Medical Center Methods and systems for converting precursor cells into gastric tissues through directed differentiation
WO2016021734A1 (ja) 2014-08-04 2016-02-11 武田薬品工業株式会社 膵前駆細胞の増殖方法
US20160177268A1 (en) 2014-12-18 2016-06-23 President And Fellows Of Harvard College Methods for generating augmented stem cell-derived beta cells and uses thereof
CN107614678B (zh) 2014-12-18 2021-04-30 哈佛学院校长同事会 干细胞来源的β细胞的产生方法及其使用方法
EP3234110B1 (en) 2014-12-18 2024-02-28 President and Fellows of Harvard College METHODS FOR GENERATING STEM CELL-DERIVED ß CELLS AND USES THEREOF
US20160175363A1 (en) 2014-12-18 2016-06-23 President And Fellows Of Harvard College Methods for generating stem cell-derived beta cells and uses thereof
WO2016100898A1 (en) 2014-12-18 2016-06-23 President And Fellows Of Harvard College Serum-free in vitro directed differentiation protocol for generating stem cell-derived b cells and uses thereof
US9974784B2 (en) 2015-01-21 2018-05-22 The Texas A&M University System Inhibitors of activin-like receptor kinases

Also Published As

Publication number Publication date
AU2023237028A1 (en) 2023-10-12
EP3008168A2 (en) 2016-04-20
KR102640729B1 (ko) 2024-02-27
SG11201510176VA (en) 2016-03-30
KR20210034688A (ko) 2021-03-30
US11162078B2 (en) 2021-11-02
KR102580225B1 (ko) 2023-09-20
DE202014011287U1 (de) 2019-02-06
US20240124847A1 (en) 2024-04-18
WO2015002724A3 (en) 2015-02-26
AU2014284677A1 (en) 2016-02-25
CA2915091A1 (en) 2014-12-18
US20240101963A1 (en) 2024-03-28
GB2549822A (en) 2017-11-01
DE112014002780T5 (de) 2016-06-23
RU2019108582A (ru) 2019-07-05
AU2014278178B2 (en) 2021-01-21
KR102205234B1 (ko) 2021-01-20
AU2020289721B2 (en) 2023-09-14
US10030229B2 (en) 2018-07-24
EP3569694A1 (en) 2019-11-20
WO2015002724A4 (en) 2015-03-26
US20230076529A1 (en) 2023-03-09
GB2531952C (en) 2019-10-09
US20190017031A1 (en) 2019-01-17
CN112226402A (zh) 2021-01-15
JP6677634B2 (ja) 2020-04-08
CN110551678A (zh) 2019-12-10
MX2015017103A (es) 2016-11-07
GB2549822B (en) 2018-05-02
BR112015030972A2 (pt) 2017-07-25
GB2531952A (en) 2016-05-04
EP3008168B1 (en) 2020-02-19
GB2557508B (en) 2018-11-07
EP3008170A4 (en) 2016-11-09
WO2014201167A4 (en) 2015-01-29
RU2019108582A3 (ru) 2021-08-04
DK3008168T3 (da) 2020-05-04
JP7354026B2 (ja) 2023-10-02
EP3008168A4 (en) 2017-05-31
JP2016531087A (ja) 2016-10-06
PH12015502767A1 (en) 2016-03-21
KR20160099079A (ko) 2016-08-19
AU2014278178A1 (en) 2016-01-28
JP2024054254A (ja) 2024-04-16
KR20230054767A (ko) 2023-04-25
US20200347358A1 (en) 2020-11-05
GB201521857D0 (en) 2016-01-27
US11078463B2 (en) 2021-08-03
SG11201510177WA (en) 2016-01-28
US20190040362A1 (en) 2019-02-07
CA2915088A1 (en) 2015-01-08
HK1257187B (zh) 2020-06-12
KR20160034892A (ko) 2016-03-30
US11104883B2 (en) 2021-08-31
US20210079355A1 (en) 2021-03-18
KR20200143750A (ko) 2020-12-24
BR112015030946A2 (pt) 2017-07-25
US20170029778A1 (en) 2017-02-02
GB201803318D0 (en) 2018-04-18
US20220396775A1 (en) 2022-12-15
US11827905B2 (en) 2023-11-28
KR20210008926A (ko) 2021-01-25
JP2020108394A (ja) 2020-07-16
GB201622354D0 (en) 2017-02-15
KR102390167B1 (ko) 2022-04-25
KR102341674B1 (ko) 2021-12-22
KR20220051442A (ko) 2022-04-26
KR102232650B1 (ko) 2021-03-29
RU2016100219A3 (ru) 2018-03-30
RU2016100219A (ru) 2017-07-17
KR102523912B1 (ko) 2023-04-21
JP6514689B2 (ja) 2019-05-15
US20150218522A1 (en) 2015-08-06
AU2023229504A1 (en) 2023-09-28
JP2021121223A (ja) 2021-08-26
SG10201710218RA (en) 2018-01-30
CN110551678B (zh) 2024-02-20
JP2019141072A (ja) 2019-08-29
BR112015030972A8 (pt) 2020-01-28
RU2692595C2 (ru) 2019-06-25
KR102423106B1 (ko) 2022-07-21
KR20230135180A (ko) 2023-09-22
MX2019003616A (es) 2019-08-01
US20200385681A1 (en) 2020-12-10
JP2016532436A (ja) 2016-10-20
US20150240212A1 (en) 2015-08-27
US20190169575A1 (en) 2019-06-06
KR20220106230A (ko) 2022-07-28
AU2020203127A1 (en) 2020-06-04
BR112015030946A8 (pt) 2020-01-28
GB2531952B (en) 2017-02-08
EP3008170A1 (en) 2016-04-20
AU2020203127C1 (en) 2023-12-21
US20220162562A1 (en) 2022-05-26
JP6893527B2 (ja) 2021-06-23
KR102631225B1 (ko) 2024-01-31
AU2014284677B2 (en) 2020-03-12
AU2020289721A1 (en) 2021-01-21
GB2557508A9 (en) 2018-09-05
KR20240014630A (ko) 2024-02-01
US10655106B2 (en) 2020-05-19
GB2557508A (en) 2018-06-20
WO2014201167A1 (en) 2014-12-18
CN106414718A (zh) 2017-02-15
AU2020203127B2 (en) 2023-06-22
KR102361924B1 (ko) 2022-02-14
KR20220025151A (ko) 2022-03-03
CN105579577A (zh) 2016-05-11
KR20210156337A (ko) 2021-12-24
WO2015002724A2 (en) 2015-01-08
JP2023093654A (ja) 2023-07-04
KR102201638B1 (ko) 2021-01-13

Similar Documents

Publication Publication Date Title
RU2016100433A (ru) КЛЕТКИ SC-β И КОМПОЗИЦИИ И СПОСОБЫ ДЛЯ ИХ СОЗДАНИЯ
Agulnick et al. Insulin-producing endocrine cells differentiated in vitro from human embryonic stem cells function in macroencapsulation devices in vivo
US10927350B2 (en) Methods for generating stem cell-derived beta cells and uses thereof
US20210060083A1 (en) Methods for generating stem cell-derived beta cells and uses thereof
RU2019101200A (ru) Генерация функциональных бета-клеток, полученных из человеческой плюрипотентной стволовой клетки, демонстрирующих реакцию в виде глюкозозависимого митохондриального дыхания и двухфазной секреции инсулина
Lysy et al. Making β cells from adult cells within the pancreas
US20190338250A1 (en) Methods for generating stem cell-derived beta cells and methods of use thereof
RU2015131838A (ru) Дифференцировка эмбриональных стволовых клеток человека в панкреатические эндокринные клетки с помощью регуляторов нв9
CN108699515A (zh) 由人多能干细胞衍生的内分泌祖细胞生成功能性β细胞
JP6789814B2 (ja) 腺性下垂体又はその前駆組織の製造方法
JP2016503654A5 (ru)
MX2011000125A (es) Diferenciacion de celulas madre pluripotentes.
RU2014130042A (ru) Дифференцировка эмбриональных стволовых клеток человека в одногормональные инсулинположительные клетки
Corritore et al. β-Cell differentiation of human pancreatic duct–derived cells after in vitro expansion
US20220389387A1 (en) Methods for amplifying and differentiating pancreatic cells, and application thereof
Rastogi et al. Environmental regulation of notochordal gene expression in nucleus pulposus cells
WO2016100925A1 (en) METHODS FOR GENERATING AUGMENTED STEM CELL-DERIVED β CELLS AND USES THEREOF
TWI438275B (zh) 促進幹細胞分化為胰島素製造細胞的方法
EP3286563B1 (en) Controlled induction of human pancreatic progenitors produces functional beta-like cells
Thakur et al. Small molecule-induced pancreatic β-like cell development: mechanistic approaches and available strategies
Gershengorn et al. Are better islet cell precursors generated by epithelial-to-mesenchymal transition?
CN105189738A (zh) 肝母细胞样细胞的培养方法及其培养物
Yagi Mendoza et al. Regeneration of insulin-producing islets from dental pulp stem cells using a 3D culture system
WO2021251418A1 (ja) 内耳前駆細胞の製造方法、内耳有毛細胞の製造方法、薬剤の評価方法、及び内耳細胞分化誘導用組成物
KR20150018348A (ko) 무단백질·무지질 배지 순화 세포주를 사용한 재조합 단백질의 제조방법